Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Alzamend Neuro Announces Topline Data From Phase 1 First-in-Human Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer’s; Data showed AL001 Is ‘bioequivalent to the marketed lithium carbonate product’

Data shows that AL001 is bioequivalent to the marketed lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar Alzamend Neuro, Inc. (NASDAQ:ALZN)

ALZN